ACTINOGEN - INTEGRATING GENOMICS-BASED APPLICATIONS TO EXPLOIT ACTINOMYCETES AS A RESOURCE FOR NEW ANTIBIOTICS (FP6-LIFESCIHEALTH) (2005-01-01 - 2009-12-31) (»add to infobox)

Paul DYSON, Mervyn BIBB, Jiri VOHRADSKY, Douglas KELL, Jens NIELSEN, Gregory Leonard CHALLIS, Wolfgang WOHLLEBEN, Colin Peter SMITH, Anna Maria PUGLIA, Lubbert DIJKHUIZEN, Marie-Joelle VIROLLE, Roderich SÜSSMUTH, Francisco MORIS, Jose A. SALAS, Juan Francisco MARTÍN, Pierre LEBLOND, Patrick ROBE, Kye Joon LEE

UNIVERSITY OF WALES SWANSEA (UKL18 - Swansea) (Great Britain), JOHN INNES CENTRE (UKH13 - Norfolk) (Great Britain), INSTITUTE OF MICROBIOLOGY - ACADEMY OF SCIENCES OF THE CZECH REPUBLIC PUBLIC RESEARCH INSTITUTION (CZ010 - Hlavni mesto Praha) (Czech Republic), THE UNIVERSITY OF MANCHESTER (UKD31 - Greater Manchester South) (Great Britain), DANMARKS TEKNISKE UNIVERSITET (DK002 - Københavns amt) (Denmark), THE UNIVERSITY OF WARWICK (UKG33 - Coventry) (Great Britain), EBERHARD-KARLS UNIVERSITAET TUEBINGEN (DE142 - Tübingen, Landkreis) (Germany), UNIVERSITY OF SURREY (UKJ23 - Surrey) (Great Britain), UNIVERSITA DEGLI STUDI DI PALERMO (ITG12 - Palermo) (Italy), RIJKSUNIVERSITEIT GRONINGEN (NL113 - Overig Groningen) (Netherlands), UNIVERSITE PARIS-SUD (FR104 - Essonne) (France), TECHNISCHE UNIVERSITAET BERLIN (DE300 - Berlin) (Germany), ENTRECHEM SL (ES120 - Asturias) (Spain), UNIVERSIDAD DE OVIEDO (ES120 - Asturias) (Spain), INSTITUTO DE BIOTECNOLOGIA DE LEON (INBIOTEC) (ES413 - León) (Spain), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR101 - Paris) (France), LIBRAGEN SA (FR716 - Rhône) (France), SEOUL NATIONAL UNIVERSITY SNU (NoRegion - NoRegion) (South Korea)

ActinoGEN is an integrated project aimed at developing novel genomics-based approaches to exploit hitherto overlooked genetic resources for new antibiotics. Drug discovery will focus on (1) accessing new antibiotic biosynthetic pathways from diverse actinomycetes that have yet to be cultured; (2) activating cryptic pathways from well-characterised actinomycetes; and (3) engineering novel hybrid antibiotics by combinatorial biosynthesis. To greatly accelerate the drug discovery process, a parallel strategy will be to engineer generic hosts optimised to produce high antibiotic yields. With the complete genome sequence of the model actinomycete, Streptomyces coelicolor, and mobilization of a pan-European effort to apply newly developed multidisciplinary post-genomic technologies, a holistic understanding of the physiology and regulation of antibiotic biosynthesis is achievable for the first time. This will, in turn, permit rational intervention to engineer generic hosts for high-yield antibiotic production. This synergy of discovery linked to overproduction will place the European biotechnology sector at the forefront of developing much-needed new antibiotics to combat multi-drug resistant pathogens.

PERSONS (18/18)

RELATED NAVIGATION AREA(S) (2/2)